Oncolytics Biotech stock: GOBLET data report 15-month response duration

Published on 10/28/2026 at 06:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Responders all survived 12 months in Cohort 4 on October 27, 2026. Oncolytics Biotech stock has a USD 46.4 million market value.

Clinical data and upcoming readouts

Oncolytics reported a 15-month median response duration in GOBLET Cohort 4 on October 27, 2026.
REO 033 plans to randomize 30 patients per arm, according to a release dated October 20, 2026.
Oncolytics Biotech has a USD 46.4 million market capitalization as of October 27, 2026.

ONCY, CA6823108759, Illustration mit AI erstellt.

Oncolytics Biotech (ISIN CA6823108759) reported a 15-month median response duration in Cohort 4 of its GOBLET study on October 27, 2026. The update covered pelareorep combined with atezolizumab in second-line or later squamous cell anal cancer, according to GlobeNewswire. All responding patients survived beyond 12 months, with multiple patients surviving beyond 24 months.

Clinical result adds durability

The company compared the 15-month response duration with 9.5 months for historical retifanlimab monotherapy in a similar patient population. That 5.5-month gap gives the result its clearest investor relevance, while median overall survival remains an open clinical endpoint.

The release also said Oncolytics plans to explore additional studies with a potential checkpoint-inhibitor partner. The company is positioning anal cancer as an entry point for a broader pelareorep and checkpoint-inhibitor strategy across human papillomavirus-driven cancers.

What does the response signal mean?

The result is a durability signal rather than a regulatory approval. The GOBLET study is being conducted at 17 centers in Germany, and its co-primary endpoints include objective response rate or disease control rate and safety, according to the October 27 release.

Three milestones shape the timeline

On October 14, 2026, Oncolytics said it expected additional data from GOBLET Cohorts 4 and 5 and a final PanCAN grant payment, according to SEC. On October 20, 2026, a company release said the REO 033 colorectal cancer study would randomize 30 patients per arm, according to Yahoo Finance. The October 27 GOBLET update then supplied the 15-month response figure.

Upcoming readouts set the next markers

Oncolytics expects final Cohort 4 results in the fourth quarter of 2026 and initial Cohort 5 results in the first half of 2027, according to the October 14 company update. The timing leaves clinical follow-through as the next concrete test for the program.

Market value and trial risk

Oncolytics had a USD 46.4 million market capitalization as of October 27, 2026. Its primary listing is Nasdaq, where the finance quote showed a last price of USD 0.46 at 4:00 p.m. ET on October 27, 2026, against a 52-week range of USD 0.44 to USD 1.32. For investors, the small market value places the clinical readouts alongside financing and regulatory execution as central valuation factors.